06Jan/14

PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from … – MarketWatch


Drug Discovery & Development

PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from
MarketWatch
showing PIXUVRI’s cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving PIXUVRI as a third- or fourth-line
UK’s NICE Issues Final Appraisal Determination on CTI Lymphoma DrugDrug Discovery & Development
Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In Seeking Alpha

all 22 news articles »

06Jan/14

Study to address exercise and vascular function in chronic kidney disease – University of Delaware


University of Delaware

Study to address exercise and vascular function in chronic kidney disease
University of Delaware
11:05 a.m., Jan. 6, 2014–Chronic kidney disease, which affects more than 20 million adults in the United States, carries with it a high risk of cardiovascular disease. In fact, even a small loss of kidney function can double a person’s risk of

06Jan/14

UK's NICE Issues Final Appraisal Determination on CTI Lymphoma Drug – Drug Discovery & Development


Drug Discovery & Development

UK’s NICE Issues Final Appraisal Determination on CTI Lymphoma Drug
Drug Discovery & Development
reviewed CTI’s updated data analysis showing Pixuvri’s cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving
PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from MarketWatch

all 10 news articles »